Premium
Effects of methotrexate and salazosulfapyridine on protein profiles of exosomes derived from a human synovial sarcoma cell line of SW982
Author(s) -
Tsuno Hirotaka,
Suematsu Naoya,
Sato Toshiyuki,
Arito Mitsumi,
Matsui Toshihiro,
Iizuka Nobuko,
Omoteyama Kazuki,
Okamoto Kazuki,
Tohma Shigeto,
Kurokawa Manae S.,
Kato Tomohiro
Publication year - 2016
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201500064
Subject(s) - methotrexate , proteome , exosome , microvesicles , synovial sarcoma , chemistry , cell culture , synovial fluid , cancer research , immunology , medicine , sarcoma , biology , microrna , pathology , biochemistry , osteoarthritis , genetics , alternative medicine , gene
Purpose To elucidate effects of salazosulfapyridine (SASP) and methotrexate (MTX), major anti‐rheumatic drugs, on exosomes derived from SW982 of a human synovial sarcoma cell line. Experimental design SW982 was treated with SASP and/or MTX under interleukin‐1β (IL‐1β)‐treated or nontreated conditions. Exosomes were isolated from the culture media, and exosomal proteome was analyzed by 2D‐DIGE. Protein spots whose intensity was significantly altered by the above treatments were identified by MS. Results Two hundred ninety‐four protein spots were detected in the exosome preparations by 2D‐DIGE. Compared to the nontreated cells, SASP‐, MTX‐, and (SASP + MTX)‐treated cells displayed 8, 10, and 21 exosomal protein spots with more than ±2.0‐fold intensity differences ( p < 0.05), respectively. Similarly, the IL‐1β‐treated cells displayed 58 exosomal protein spots with more than ±1.5‐fold intensity differences ( p < 0.05). In about half of the 58 spots, the IL‐1β‐induced intensity changes were suppressed by simultaneous addition of SASP and/or MTX. Most of the identified proteins were immunity‐ or anti‐oxidation‐related proteins. Conclusions and clinical relevance The SASP and/or MTX treatments altered the protein profiles of exosomes and suppressed the effects of IL‐1β on the exosomal proteome. Exosomes may play roles in the actions of these anti‐rheumatic drugs.